What is the recommended treatment approach for symptomatic adenomyosis?

Treatment of Symptomatic Adenomyosis

For symptomatic adenomyosis, start with a levonorgestrel-releasing intrauterine system (LNG-IUS) as first-line therapy for bleeding and pain symptoms, as it provides superior outcomes compared to combined oral contraceptives and addresses the disease locally with minimal systemic effects 1.

Treatment Algorithm Based on Clinical Context

First-Line Medical Management

Hormonal therapy is the cornerstone of conservative management:

• Progestin IUD (LNG-IUS): Preferred initial treatment due to local mechanism of action, lower systemic hormone levels, long duration after placement, and user independence. A recent randomized controlled trial demonstrated significant improvement in both pain and bleeding compared to combined oral contraceptives 1.

• Alternative hormonal options: Combined oral contraceptives or GnRH antagonist combinations are effective, with pooled analysis showing that concomitant adenomyosis does not decrease effectiveness for heavy menstrual bleeding 1.

• Important limitation: Medical therapies will NOT treat bulk symptoms (pressure, fullness, bladder/bowel symptoms) 1.

Second-Line: Uterine Artery Embolization (UAE)

When medical management fails and the patient desires uterus preservation, UAE is the next appropriate step:

• Meta-analysis shows 94% short-term (<12 months) and 85% long-term (>12 months) symptom improvement 1.
• Only 7% require hysterectomy for persistent symptoms 1.
• Effective for both pure adenomyosis and adenomyosis with coexisting fibroids 2.
• Long-term data (up to 7 years) demonstrates sustained quality of life improvement with 18% eventual hysterectomy rate 1.
• Recent systematic review confirms 76.4% of patients experience significant improvement in heavy menstrual bleeding, dysmenorrhea, and bulk symptoms 3.

Critical counseling point: Comprehensive fertility and pregnancy data after UAE for adenomyosis is lacking; patients must understand this limitation 1.

Definitive Treatment: Hysterectomy

Hysterectomy provides definitive resolution but carries significant risks:

• Accounts for three-quarters of treatment in the United States 1.
• Treats concomitant adenomyosis definitively when other indications exist 1.

Major concerns with hysterectomy (even with ovarian preservation):

• Elevated cardiovascular disease risk 1
• Increased mood disorders 1
• Increased mortality, especially when performed at young age 1
• Increased risk of osteoporosis, bone fracture, and dementia 1

Randomized studies show hysterectomy has increased severe complications, longer hospitalization, and longer recovery compared to UAE despite similar symptom relief 1, making it appropriate only when less invasive options have failed or are contraindicated.

If hysterectomy is necessary: Use the least invasive route—vaginal or laparoscopic approaches are superior to abdominal hysterectomy for recovery time, complications, and quality of life 1.

Treatments with Insufficient Evidence

The following lack relevant literature for adenomyosis treatment:

• MR-guided focused ultrasound (MRgFUS) 1
• Endometrial ablation (associated with treatment failure in adenomyosis) 1
• Myomectomy (hysteroscopic, laparoscopic, or open) 1
• Laparoscopic uterine artery occlusion 1

Common Pitfalls to Avoid

1. Don't skip medical management: Jumping directly to invasive procedures bypasses effective, low-risk options.

2. Don't use medical therapy for bulk symptoms: Hormonal treatments only address bleeding and pain, not pressure/mass effects 1.

3. Don't perform hysterectomy as first-line: Given the significant long-term cardiovascular, bone, and cognitive risks, exhaust less invasive options first 1.

4. Don't assume UAE compromises all future fertility: While data is limited, successful pregnancies have been reported; counsel patients appropriately rather than categorically excluding this option 1.

5. Recognize endometrial ablation failure: The presence of adenomyosis is associated with treatment failure of endometrial ablation 1.

Clinical Decision Framework

Step 1: Bleeding/pain dominant symptoms WITHOUT bulk symptoms → LNG-IUS

Step 2: Medical therapy failure OR bulk symptoms present → UAE (if uterus preservation desired)

Step 3: UAE failure OR no desire for uterus preservation OR concurrent indications (malignancy, prolapse) → Hysterectomy (least invasive route)

This stepwise approach prioritizes quality of life while minimizing morbidity and mortality risks associated with more invasive interventions.